On the one hand, the dysregulation of necroptosis regulatory molecules such as MLKL and RIPK3 is associated with cancer development (70–72), and the activation of RIPK1/RIPK3 may potentiate antitumor immunity (73) and reverses drug resistance (70). The gene discussed is RIPK1; the disease is cancer.